Roche Holding AG (XSWX:RO) Growth Rank: 4 (As of Jul. 06, 2026) — Near Median


XSWX:RO Roche Holding AG XSWX:RO
75 GF Score
Price CHF346.20
GF Value CHF269.24
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Growth Rank?

Roche Holding AG XSWX:RO -0.29% 75 Growth Rank is 4 as of Jul. 06, 2026, which is at its 10-year median of 4.00. GuruFocus rates XSWX:RO with a GF Score™ of 75/100 and a GF Value™ of CHF269.24 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Roche Holding AG has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Roche Holding AG Growth Rank Related Terms

XSWX:RO vs LLY, JNJ, ABBV: Growth Rank Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Growth Rank distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Growth Rank falls into.


XSWX:RO
75GF Score
Roche Holding AG XSWX:RO
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Roche Holding AG (XSWX:RO) has a Growth Rank of 4 as of Jul. 06, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Roche Holding AG and its competitors. This is near median its historical median of 4.00. Over the past decade, Roche Holding AG's Growth Rank has ranged from 2.00 to 9.00.
Is Roche Holding AG's Growth Rank too high?
Roche Holding AG's current Growth Rank of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, Roche Holding AG has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Growth Rank compare to LLY and JNJ?
Roche Holding AG's Growth Rank of 4 can be compared against companies in the Drug Manufacturers industry. Historically, Roche Holding AG's own Growth Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current Growth Rank is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF269.24, compared to a current price of CHF346.20 — trading 28.6% above its estimated fair value. The current Growth Rank is 4, which is near median its 10-year median of 4.00. Roche Holding AG's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Growth Rank is 4 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF346.20 is trading 28.6% above its estimated GF Value™ of CHF269.24. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:RO:

  • Growth Rank: 4 (near median its 10-year median of 4.00)
  • GF Value™: CHF269.24 vs. price of CHF346.20 (28.6% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
75GF Score

Get the complete analysis for XSWX:RO

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF346.20
Price
CHF269.24
GF Value